27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Stifel analyst Thomas Shrader laid out three scenarios for Medivation Inc (NASDAQ: MDVN) takeover after the biopharma company rejected Sanofi SA (ADR) (NYSE: SNY)'s $52.50 acquisition bid.
Shrader raised his target price on the stock by $14 to $66, which is also his minimum takeover price for Medivation.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
"Overall, we think the ability of a company to enter the growing arena of metastatic castrate-resistant prostate cancer (mCRPC) with a drug as good as xtandi is relatively unique and we expect any deal to get done at a minimum of about $66 per share with an additional conditional payout for Talazoparib," Shrader wrote in a note.
Shrader, who has a Buy rating on the stock, laid out the following three scenarios that could fetch as much as $85 for Medivation.
Scenario 1:Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Last week, Goldman Sachs said it expects potential takeout value of Medivation near $70 a share.
AT time of writing, shares of Medivation were down 0.62 percent to $57.44.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.